Antibodies specifically reactive with a tumor necrosis factor related ligand
View Patent ↗The present invention relates to Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.
1. A substantially pure antibody or antigen-binding portion thereof that is specifically reactive with a substantially pure polypeptide consisting essentially of amino acids 36 to 284 of SEQ ID NO: 4.
2. A substantially pure antibody or antigen-binding portion thereof that is specifically reactive with a substantially pure polypeptide consisting of amino acids 36 to 284 of SEQ ID NO: 4.
3. A substantially pure antibody or antigen-binding portion thereof that is specifically reactive with a substantially pure polypeptide that consists of a fragment of SEQ ID NO:4, wherein the amino terminus of the fragment is at any one of amino acids 81 to 139 of SEQ ID NO: 4.
4. A substantially pure antibody or antigen-binding portion thereof that is specifically reactive with a substantially pure polypeptide consisting essentially of SEQ ID NO: 2.
5. A substantially pure antibody or antigen-binding portion thereof that is specifically reactive with a substantially pure polypeptide consisting of SEQ ID NO: 2.
6. A substantially pure antibody or antigen-binding portion thereof that is specifically reactive with a substantially pure polypeptide that consists of a fragment of SEQ ID NO:2, wherein the amino terminus of the fragment is at any one of amino acids 22 to 88 of SEQ ID NO: 2.
7. The antibody or antigen-binding portion thereof according to any one of claims 1 – 6 , wherein said antibody or antigen-binding portion thereof is a monoclonal antibody.
8. The antibody or antigen-binding portion thereof according to any one of claims 1 – 6 , wherein said antibody or antigen-binding portion thereof is a polyclonal antibody.
9. The antibody or antigen-binding portion according to any one of claims 1 – 6 that is an antibody fragment thereof.
10. The antibody or antigen-binding portion thereof according to any one of claims 1 – 6 , wherein said antibody or antigen-binding portion thereof is a chimeric antibody.
11. The antibody or antigen-binding portion thereof according to any one of claims 1 – 6 , wherein said antibody or antigen-binding portion thereof is a humanized antibody.
12. The antibody or antigen-binding portion thereof according to any one of claims 1 – 6 , wherein said antibody or antigen-binding portion thereof is a recombinant antibody.
13. The antibody or antigen-binding portion according to claim 9 that is a Fab′ fragment.
14. The antibody or antigen-binding portion according to claim 9 that is a F(ab′)2 fragment.
15. A composition comprising the antibody or antigen-binding portion thereof according to claim 12 and a pharmaceutically acceptable carrier.
16. A method for producing a substantially pure antibody or antigen-binding portion thereof which is specifically reactive with a substantially pure polypeptide comprising amino acids 36 to 284 of SEQ ID NO: 4 or an immunogenic portion of amino acids 36 to 284 of SEQ ID NO:4, comprising the step of immunizing an animal with said polypeptide, and isolating said antibody from said animal.
17. A method for producing a substantially pure antibody or antigen-binding portion thereof which is specifically reactive with a substantially pure polypeptide comprising SEQ ID NO: 2 or an immunogenic portion of SEQ ID NO:2, comprising the step of immunizing an animal with said polypeptide, and isolating said antibody from said animal.
18. A composition comprising the antibody or antigen-binding portion according to claim 7 and a pharmaceutically acceptable carrier.
19. A composition comprising the antibody or antigen-binding portion according to claim 11 and a pharmaceutically acceptable carrier.